Table 2.
Clinical data based on RET and RAS mutational status in sporadic MTCs.
| RET+/RAS− n = 39 (%) |
RET−/RAS− n = 58 (%) |
RAS+/RET− n = 91 (%) |
p | |
|---|---|---|---|---|
| Median calcitonin level in pg/ml at diagnosis (n = 106) | 700 (83–22931) | 331 (20–42300) | 402 (61–747) | 0.01 |
| Stage | ||||
| I-II (n = 66) | 18 (46%) | 41 (71%) | 7 (78%) | 0.03 |
| III-IV (n = 40) | 21 (54%) | 17 (29%) | 2 (22%) | |
| Lymph node metastases (n = 40) | 21 (54%) | 17 (29%) | 2 (22%) | 0.03 |
| Biochemical cure2 (n = 64) | 18 (46%) | 38 (67%) | 8 (89%) | 0.03 |
| Disease progression (n = 15) | 9 (24%) | 6 (10%) | 0 | 0.08 |
| Disease-related death3 (n = 9) | 7 (18%) | 2 (4%) | 0 | 0.03 |
1One patient with a novel RAS mutation was excluded from statistical analysis. 2Ct level was unavailable for one patient. 3Two patients were lost to follow-up.